<div class="event-nav">
    <div class="button-group">
        <div class="button-container">
            <button data-uri="/html/{lang}/events/vasoplegia-actions.html" data-title="Vasoplegia" class="bg-actions">Actions</button>
        </div>
        <div class="button-container">
            <button data-uri="/html/{lang}/events/vasoplegia-summary.html" data-title="Vasoplegia" class="bg-summary">Summary</button>
        </div>
        <div class="button-container">
            <button data-uri="/html/{lang}/events/vasoplegia-ddx.html" data-title="Vasoplegia" class="bg-ddx">DDx</button>
        </div>
        <div class="button-container">
            <button data-uri="/html/{lang}/events/vasoplegia-tx.html" data-title="Vasoplegia" class="bg-tx">Tx</button>
        </div>
        <div class="button-container">
            <button data-uri="/html/{lang}/events/vasoplegia-other.html" data-title="Vasoplegia" class="bg-other">Other</button>
        </div>
    </div>
    <div class="bg-summary event-title">Summary</div>
</div>
<div class="page">
    Vasoplegic Syndrome (VPS) is defined as systemic hypotenion in the setting of decreased systemic vascular resistance (SVR) and normal or increased cardiac index (CI). The risk of VPS increases with numerous preoperative risk factors, particularly including the preoperative use of ACE-I, CCB, and amiodarone.  VPS is often refractory to standard interventions to treat hypotension on CBP.  Mulitmodal/multi-receptor therapy is recommended, including catecholiminergic and noncatecholiminergic vasopressor infusions and inhibitors of peripheral vascular smooth muscle relaxation (methylene blue and hydroxycobalamin). Perioperative vasoplegia, especially catecholimine-resistant VPS, carries signficant increase in risk of perioperative major morbidity and mortality.
 </div>